New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...
Japan’s Shionogi (TYO: 4507) yesterday delivered a late-breaking scientific oral presentation at the Conference of ...
The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close contact with someone who is infected vulnerable to developing COVID ...
An open letter to US Secretary of State Marco Rubio signed by hundreds of high-profile HIV doctors, researchers and public ...
Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...
But what if you could avoid getting COVID-19 altogether? That’s the potential promise of a new study on a drug made by ...
The Punch on MSN20h
USAID cuts causing ‘catastrophic harm’ doctors tell TrumpHundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, ...
Health and Me on MSN3h
Yearly Jab For HIV Protection Is Now Almost HereA yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.
On March 7, 2025, and again on March 10, scientists, healthcare workers, and more rallied in protest to Trump administration ...
New research into how a retrovirus is spreading across populations of wild koalas in Queensland, Australia is leading to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback